Diquafosol was licensed for certain ophthalmic uses from Inspire and Diquas Ophthalmic Solution 3% was developed by Santen as a treatment for dry eye.
Reportedly, in clinical studies conducted in Japan, Diquas Ophthalmic Solution 3% was shown to improve dry eye symptoms by promoting secretion of mucin and water, thereby bringing the tear film closer to a normal state. In addition, no serious ocular or systemic adverse drug reactions were found during the clinical trials.
Santen currently markets ‘Hyalein Ophthalmic Solution 0.1%’ and several other dry eye treatment products. The addition of ‘Diquas Ophthalmic Solution 3%’ to the Santen product lineup is expected to increase treatment choices for medical professionals, and contribute to improving QOL (quality of life) for dry eye patients.